<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of anthrax</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of anthrax</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of anthrax</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth H Wilson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H193168587"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The incidence of anthrax in humans has decreased during the past century, and it is now very rare in developed countries including the United States. However, anthrax remains a concern in the developed world because of its potential as an agent of bioterrorism. Anthrax meningitis and the fulminant phase of inhalation anthrax are associated with extremely high mortality rates.</p><p>The treatment of anthrax will be reviewed here. The microbiology, pathogenesis, epidemiology, clinical manifestations, diagnosis, and prevention of anthrax are discussed separately. (See  <a class="medical medical_review" href="/d/html/5506.html" rel="external">"Microbiology, pathogenesis, and epidemiology of anthrax"</a> and  <a class="medical medical_review" href="/d/html/5533.html" rel="external">"Clinical manifestations and diagnosis of anthrax"</a> and  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax"</a>.)</p><p class="headingAnchor" id="H193169871"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment recommendations presented here are in agreement with the recommendations of the United States Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) [<a href="#rid1">1-3</a>].</p><p class="headingAnchor" id="H1135540807"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Treatment of patients suspected of having systemic anthrax should be started urgently and should include intravenous antimicrobial combination therapy and antitoxin (<a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a>, <a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">obiltoxaximab</a> or <a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">anthrax immunoglobulin</a>), drainage of pleural effusions, supportive care, and consideration of adjunctive glucocorticoids [<a href="#rid1">1</a>]. Each of these therapies is discussed in detail below. When selecting an antimicrobial regimen for anthrax, the production of toxin, the potential for antimicrobial drug resistance, the frequent occurrence of meningitis, and the presence of latent spores must be taken into account. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contact public health officials</strong> – In the United States, anthrax is an immediately notifiable disease, meaning that as soon as clinicians reasonably suspect the diagnosis, they should contact the state health department for assistance in diagnosis and treatment. Since antitoxin treatment is available only through the Strategic National Stockpile, clinicians can obtain them only through a state health department, which coordinates with the CDC. (See <a class="local">'Public health reporting'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – Patients suspected of having systemic anthrax should undergo similar testing as is done in other patients with an acute febrile illness, including pretreatment blood cultures and other appropriate cultures [<a href="#rid1">1</a>]. Unless it is contraindicated, all patients suspected of having systemic anthrax should undergo lumbar puncture to evaluate for meningitis. Other diagnostic testing is discussed separately. (See  <a class="medical medical_review" href="/d/html/5533.html" rel="external">"Clinical manifestations and diagnosis of anthrax", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospital admission</strong> – All patients with systemic anthrax should be hospitalized [<a href="#rid1">1</a>]. Systemic anthrax is defined as cutaneous anthrax with systemic involvement; gastrointestinal, injection, or inhalation anthrax; anthrax meningitis; or bacteremia. Because inhalation anthrax can have a prodromal phase followed by a fulminant phase characterized by sudden decompensation, hospitalized patients should have careful hemodynamic monitoring, including continuous pulse oximetry and telemetry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Principles of antimicrobial regimen selection</strong> – Recommended antimicrobial regimens for anthrax include bactericidal agents because of their immediate killing effect and a protein synthesis inhibitor to suppress toxin production [<a href="#rid1">1,4</a>]. Although there is not strong direct evidence supporting this recommendation in anthrax, the benefit of inhibiting toxin production has been demonstrated for streptococcal toxic shock syndrome and clostridial sepsis. (See  <a class="medical medical_review" href="/d/html/3169.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention", section on 'General principles'</a> and  <a class="medical medical_review" href="/d/html/7672.html" rel="external">"Clostridial myonecrosis", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><em>Bacillus anthracis</em> is highly susceptible to a variety of antimicrobial agents including penicillin, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a>, carbapenems, <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, and fluoroquinolones [<a href="#rid4">4-8</a>]. <em>B. anthracis</em> is <strong>not</strong> susceptible to cephalosporins or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid5">5-7,9,10</a>]. Because <em>B. anthracis</em> possesses beta-lactamase genes, beta-lactam use can induce resistance during treatment; penicillin or <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> use therefore warrants a high index of suspicion for emergence of resistance [<a href="#rid1">1,11</a>]. Although the few penicillin-resistant isolates tested have been sensitive to <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, that agent is only expected to inhibit one of the two beta-lactamase gene products of <em>B. anthracis</em> [<a href="#rid12">12</a>]. Thus, pending more experience, amoxicillin-clavulanate and <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> are not good choices for penicillin-resistant strains. </p><p></p><p class="bulletIndent1">Clinical microbiologists should also be aware that the antibiotic breakpoints for <em>B. anthracis</em> are in some cases different from those of <em>Bacillus</em> species in general [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent oral therapy</strong> – If the infection is bioterrorism associated or if aerosol exposure is suspected, patients should switch to single agent oral therapy  (<a class="graphic graphic_table graphicRef58905" href="/d/graphic/58905.html" rel="external">table 1</a>) following the initial intravenous regimen to complete a 60-day total course of antibiotics (inclusive of initial therapy) in order to prevent relapse from surviving <em>B. anthracis</em> spores  (<a class="graphic graphic_table graphicRef58905" href="/d/graphic/58905.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. The oral antimicrobial options for postexposure prophylaxis are discussed in detail elsewhere  (<a class="graphic graphic_table graphicRef58905" href="/d/graphic/58905.html" rel="external">table 1</a>). Pediatric experts recommend that children potentially exposed to aerosolized anthrax spores also receive anthrax vaccination in addition to prophylactic antibiotics [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax", section on 'Antimicrobial regimen selection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of meningitis</strong> – Meningitis and hemorrhagic brain infection have been observed in up to one-half of systemic anthrax cases; thus, meningitis must be considered in all cases of systemic anthrax [<a href="#rid1">1</a>]. In a mass casualty situation, especially if resources become limited, it may be necessary to use clinical criteria for the diagnosis of meningitis [<a href="#rid15">15,16</a>]. (See <a class="local">'Meningitis'</a> below and  <a class="medical medical_review" href="/d/html/5533.html" rel="external">"Clinical manifestations and diagnosis of anthrax", section on 'Meningitis'</a>.)</p><p></p><p class="headingAnchor" id="H108206856"><span class="h2">Antimicrobial selection and duration</span></p><p class="headingAnchor" id="H527599603"><span class="h3">Meningitis</span><span class="headingEndMark"> — </span>Early and aggressive multidrug therapy of anthrax meningitis is crucial due to the rapid progression and high mortality of the disease [<a href="#rid17">17-19</a>]. Empiric treatment for anthrax cases in which anthrax meningitis cannot be ruled out should include intravenous therapy with at least three antimicrobial agents with activity against <em>B. anthracis</em>, including at least two agents with bactericidal activity, and at least one protein synthesis inhibitor (to reduce exotoxin production) [<a href="#rid1">1,2</a>]. All agents should also have good central nervous system (CNS) penetration. Following initial intravenous antimicrobial therapy, an oral regimen is recommended to prevent relapse. An antitoxin (<a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a>, <a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">obiltoxaximab</a>, or <a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">anthrax immunoglobulin</a>) is also recommended for initial therapy. (See <a class="local">'Antitoxins'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial intravenous regimen</strong> – For patients with systemic anthrax with potential meningitis and normal renal function, we suggest [<a href="#rid1">1,2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> – In adults: 400 mg intravenously (IV) every 8 hours; in children: 30 mg/kg per day divided every 8 hours, not to exceed 400 mg per dose</p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">Meropenem</a> – In adults: 2 g IV every 8 hours; in children: 120 mg/kg per day divided every 8 hours, not to exceed 2 g per dose<strong> </strong></p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> – In adults and children ≥12 years of age: 600 mg IV every 12 hours; in children &lt;12 years of age: 30 mg/kg per day divided every 8 hours, not to exceed 600 mg per dose</p><p></p><p class="bulletIndent1">First-line and alternative agents are reviewed in the following table  (<a class="graphic graphic_table graphicRef96170" href="/d/graphic/96170.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> is the agent of choice for the bactericidal component of therapy based upon efficacy data in nonhuman primate infection models and experience with its use for anthrax cases in humans [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> and <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> are acceptable alternatives. The fluoroquinolones have adequate CNS penetration. There have been no reports of naturally occurring resistance of <em>B. anthracis</em> to fluoroquinolones.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">Meropenem</a> is the agent of choice as the second bactericidal agent for treatment of possible meningitis [<a href="#rid1">1</a>]. The carbapenems are highly resistant to beta-lactamases and have good CNS penetration. If meropenem is not available, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> is an acceptable alternative. However, imipenem should be used with caution in patients with meningitis since it is associated with an increased seizure risk. For <em>B. anthracis</em> isolates with confirmed susceptibility to penicillin, IV <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a>, or <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> is an acceptable alternative to the carbapenem. If beta-lactam agents are not available, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> is an alternative agent for children [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> is the preferred protein synthesis inhibitor [<a href="#rid1">1</a>]. It is favored over <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> because it is likely to have better CNS penetration [<a href="#rid1">1,20</a>]. Potential toxicities of linezolid include myelosuppression, peripheral and optic neuropathies, and serotonin syndrome [<a href="#rid1">1</a>]. Linezolid should be used with caution in patients with pre-existing myelosuppression or on selective serotonin reuptake inhibitors (SSRIs). Clindamycin is an acceptable alternative if linezolid is unavailable or is not tolerated. <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> is not a protein synthesis inhibitor, but it has been used for its synergistic effect with other agents. Rifampin can be used if linezolid and clindamycin are unavailable. <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a> is a protein synthesis inhibitor with good CNS penetration. Where available, chloramphenicol can be used if linezolid, clindamycin, and rifampin are unavailable. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is not recommended for adults with suspected meningitis because it does not have adequate CNS penetration [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Considerations during and after pregnancy</strong> – The treatment of pregnant, lactating, and postpartum women is similar to the treatment of nonpregnant adults, except that in pregnant individuals, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> is even more strongly preferred as one of the bactericidal agents because it crosses the placental barrier [<a href="#rid3">3</a>]. If ciprofloxacin is not used, another agent that crosses the placenta should be included in the regimen. Such agents are listed in the table  (<a class="graphic graphic_table graphicRef96170" href="/d/graphic/96170.html" rel="external">table 2</a>). Because pregnancy can affect drug metabolism, clinicians should consult a clinical pharmacist, if available, for assistance with drug dosing in pregnant patients. Pharmacokinetic data indicate that penicillin, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, and carbapenems may require higher doses in pregnant and postpartum women than those recommended for nonpregnant adults [<a href="#rid3">3,21</a>].<strong> </strong>Serum levels of ciprofloxacin were also lower in pregnant individuals in one study [<a href="#rid22">22</a>].<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of initial therapy</strong> – For patients being treated for anthrax meningitis, IV combination therapy should be continued for at least three weeks or until the patient is clinically stable, whichever is longer [<a href="#rid1">1</a>]. All clinical signs and symptoms and laboratory and imaging studies should show resolution of inflammation before antimicrobial therapy is discontinued [<a href="#rid2">2</a>]. In some patients, IV therapy will be necessary for three to six weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent oral therapy</strong> – Once the course of IV combination therapy has been completed, patients should be switched to single agent oral therapy  (<a class="graphic graphic_table graphicRef58905" href="/d/graphic/58905.html" rel="external">table 1</a>) to complete a 60-day postexposure prophylactic course of antibiotics (inclusive of initial therapy) in order to prevent relapse from surviving <em>B. anthracis</em> spores [<a href="#rid1">1</a>]. The oral antimicrobial options for and duration of postexposure prophylaxis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax", section on 'Antimicrobial regimen selection'</a>.)</p><p></p><p>Adjunctive measures (including glucocorticoids and surgery) and supportive care are discussed below. (See <a class="local">'Adjunctive therapies'</a> below and <a class="local">'Supportive care'</a> below.)</p><p class="headingAnchor" id="H527599864"><span class="h3">Systemic anthrax without meningitis</span><span class="headingEndMark"> — </span>Systemic anthrax without meningitis includes inhalation, injection, and gastrointestinal anthrax and cutaneous anthrax with systemic involvement; meningitis should be ruled out in all patients [<a href="#rid1">1</a>]. Patients with cutaneous anthrax with extensive edema or lesions of the head or neck should also be treated according to the recommendations for systemic anthrax. Antimicrobial therapy should be initiated promptly in any patient with suspected systemic anthrax. Initial therapy should include at least two IV agents with activity against <em>B. anthracis</em>, at least one agent with bactericidal activity, and at least one protein synthesis inhibitor  (<a class="graphic graphic_table graphicRef74184" href="/d/graphic/74184.html" rel="external">table 3</a>). Following initial intravenous antimicrobial therapy, an oral regimen is recommended to prevent relapse. An antitoxin (<a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a>, <a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">obiltoxaximab</a>, or <a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">anthrax immunoglobulin</a>) is also recommended for initial therapy. (See <a class="local">'Antitoxins'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial intravenous regimen</strong> – For adults with systemic anthrax and normal renal function in whom meningitis has been ruled out, we suggest [<a href="#rid1">1,3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> 400 mg intravenously (IV) every 8 hours<strong> </strong></p><p></p><p class="bulletIndent2"><strong>PLUS </strong>one of the following: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> 900 mg IV every 8 hours <strong>or</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> 600 mg IV every 12 hours</p><p></p><p class="bulletIndent1">If the <em>B. anthracis</em> strain is susceptible to penicillin, <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> is considered equivalent to the fluoroquinolone option for primary bactericidal treatment.</p><p></p><p class="bulletIndent1">For children with systemic anthrax in whom meningitis has been ruled out, we suggest [<a href="#rid2">2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One of the following: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> 30 mg/kg per day IV divided every 8 hours (not to exceed 400 mg/dose)<strong> or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For penicillin-susceptible strains only, <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> 400,000 units/kg per day IV divided every 4 hours (not to exceed 4 million units/dose)<strong> </strong></p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> 40 mg/kg per day IV divided every 8 hours (not to exceed 900 mg/dose)</p><p></p><p class="bulletIndent1">First-line and alternative agents are reviewed in the following table  (<a class="graphic graphic_table graphicRef74184" href="/d/graphic/74184.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent1">Most data on the treatment of anthrax predate the availability of many of the antimicrobial agents that are recommended and/or are derived from animal studies [<a href="#rid1">1</a>]. In a systematic review of 82 cases of inhalation anthrax between 1900 and 2005, the 11 patients in the 2001 United States bioterrorist attack were significantly less likely to die than historical controls (45 versus 92 percent); they were also more likely to receive antibiotics during the prodromal phase of illness (64 versus 13 percent), multidrug regimens (≥2 antimicrobial agents or antiserum plus antimicrobial therapy; 91 versus 50 percent), and pleural fluid drainage (73 versus 11 percent) [<a href="#rid17">17</a>]. Patients who progressed to the fulminant phase had a mortality rate of 97 percent regardless of the treatment they received. All patients with anthrax meningoencephalitis died. </p><p></p><p class="bulletIndent1">Three antimicrobial agents have received US Food and Drug Administration (FDA) approval for the treatment of anthrax, including inhalation anthrax: <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, and <a class="drug drug_general" data-topicid="9750" href="/d/drug information/9750.html" rel="external">penicillin G procaine</a> (although the last has been discontinued) [<a href="#rid23">23,24</a>]. The multidrug regimens found to be effective in the treatment of patients with inhalation anthrax during the 2001 bioterrorism attacks included ciprofloxacin plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> plus either <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> or <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Considerations during and after pregnancy</strong> – The treatment of pregnant, lactating, and postpartum women is similar to the treatment of nonpregnant adults, except that <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> is strongly preferred as the bactericidal agent because it crosses the placental barrier [<a href="#rid3">3</a>]. If ciprofloxacin is not included in the regimen, a different agent that crosses the placental barrier should be included in the regimen. Appropriate choices are listed in the table  (<a class="graphic graphic_table graphicRef74184" href="/d/graphic/74184.html" rel="external">table 3</a>). Because pregnancy can affect drug metabolism, clinicians should consult a clinical pharmacist, if available, for assistance with drug dosing in pregnant patients. Pharmacokinetic data indicate that penicillin, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, and carbapenems may require higher doses in pregnant and postpartum women than those recommended for nonpregnant adults [<a href="#rid3">3,21</a>]. Serum levels of ciprofloxacin were also lower in pregnant individuals in one study [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of initial therapy and transition to a subsequent oral regimen </strong>– Patients should be treated with IV therapy for at least two weeks or until clinically stable, whichever is longer [<a href="#rid1">1</a>]. Once the course of IV combination therapy has been completed, patients should be switched to single agent oral therapy  (<a class="graphic graphic_table graphicRef58905" href="/d/graphic/58905.html" rel="external">table 1</a>) to complete a 60-day postexposure prophylactic course of antibiotics (inclusive of initial therapy) in order to prevent relapse from surviving <em>B. anthracis</em> spores [<a href="#rid1">1</a>]. The oral antimicrobial options for and duration of postexposure prophylaxis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax", section on 'Antimicrobial regimen selection'</a>.)</p><p></p><p class="bulletIndent1">Children who appear to be well and have no ongoing signs or symptoms of active infection may be transitioned to oral monotherapy before completing two weeks of IV combination therapy [<a href="#rid2">2,14</a>]. More detailed recommendations can be found in <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fpediatrics.aappublications.org%2Fcontent%2F133%2F5%2Fe1411.full.pdf%2Bhtml&amp;token=2QELdqQSqwq6zGZXXI56rJ8JkEtmOsxmTdrQlZCvLO%2FzHGVnCtiiQNvLPBrNaudBZZtHnqaSsVskXe96slHgwVEbekTDlXQDSodgAxm7jSk%3D&amp;TOPIC_ID=15309" target="_blank">American Academy of Pediatrics guidelines</a> on anthrax management.</p><p></p><p>Adjunctive measures (including glucocorticoids and surgery) and supportive care are discussed below. (See <a class="local">'Adjunctive therapies'</a> below and <a class="local">'Supportive care'</a> below.)</p><p class="headingAnchor" id="H193169878"><span class="h3">Cutaneous anthrax without systemic involvement</span><span class="headingEndMark"> — </span>The recommendations in this section are intended for patients with cutaneous anthrax <strong>without</strong> systemic involvement, extensive edema, or lesions of the head or neck. Patients with cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck should be treated according to the recommendations presented above for systemic anthrax. (See <a class="local">'Systemic anthrax without meningitis'</a> above and <a class="local">'Meningitis'</a> above.)</p><p>For cutaneous anthrax without systemic involvement, we recommend monotherapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpregnant adults</strong> — For nonpregnant adults, we suggest oral therapy with [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> 500 mg every 12 hours <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> 100 mg every 12 hours <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> 750 mg every 24 hours <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">Moxifloxacin</a> 400 mg every 24 hours</p><p></p><p class="bulletIndent1">Alternatives include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> 600 mg every 8 hours <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For penicillin-susceptible strains, penicillin VK 500 mg every 6 hours <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For amoxicillin-susceptible strains, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> 1 g every 8 hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant, lactating, and postpartum</strong> <strong>women</strong> — For pregnant, lactating, and postpartum women, the agent of choice is <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 mg orally every 12 hours [<a href="#rid3">3</a>]. If ciprofloxacin is unavailable, alternative agents that are likely to cross the placenta adequately include <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and penicillin; amoxicillin or penicillin can be used for amoxicillin- or penicillin-susceptible strains, respectively. <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> are also likely to cross the placenta, but data are limited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> — For children, we suggest one of the following oral agents [<a href="#rid2">2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> 30 mg/kg per day divided every 12 hours (not to exceed 500 mg/dose) <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For amoxicillin-susceptible strains, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> 75 mg/kg per day divided every 8 hours (not to exceed 1 g/dose)</p><p></p><p class="bulletIndent1">Alternatives include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> 4.4 mg/kg per day divided every 12 hours (not to exceed 100 mg/dose) <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> 30 mg/kg per day divided every 8 hours (not to exceed 600 mg/dose) <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>&lt;50 kg: 16 mg/kg per day divided every 12 hours (not to exceed 250 mg/dose)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>≥50 kg: 500 mg every 24 hours <strong>OR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For penicillin-susceptible strains, penicillin VK 50 to 75 mg/kg per day divided every 6 to 8 hours</p><p></p><p>Adequate dosing of penicillin and <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> is particularly important because resistance may emerge during treatment with subtherapeutic doses of these agents [<a href="#rid1">1</a>].</p><p>For naturally acquired infection (eg, animals with anthrax, hides from animals with anthrax), the duration of therapy is 7 to 10 days. For bioterrorism-associated cases and cases in which an aerosol exposure is suspected, a longer course for postexposure prophylaxis is given. (See <a class="local">'Overview'</a> above.)</p><p class="headingAnchor" id="H108206558"><span class="h2">Antitoxins</span><span class="headingEndMark"> — </span>Antitoxin therapies are a recommended component of treatment of systemic anthrax, with or without meningitis, and are used in combination with antimicrobial therapy. These include the monoclonal antibodies <a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a> and <a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">obiltoxaximab</a> as well as anthrax immunoglobin derived from human plasma. They inhibit binding of protective antigen and translocation of the two primary toxins, lethal toxin (LT) and edema toxin, into cells [<a href="#rid1">1</a>]. These agents may have their greatest benefit when used early in the course of disease [<a href="#rid26">26</a>]. In the United States. supplies are held in the Strategic National Stockpile for use by the CDC in the event of an anthrax emergency. Thus, they are only used by consultation with the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fanthrax&amp;token=mjmpv7xMHRIW2nr%2B3NCnsWBEHHz6w9xdJBh7Z08pBSlwipUBRab2%2FGhn3tyWNQl6&amp;TOPIC_ID=15309" target="_blank">CDC</a> through the state health department, should be consulted as soon as anthrax is reasonably suspected.</p><p>Data supporting the use of antitoxin therapy are limited. Animal origin antiserum was used with some success in the treatment of anthrax prior to the advent of antimicrobial therapy [<a href="#rid27">27-29</a>]. In a systematic review of inhalation anthrax cases from 1900 to 2005, mortality was significantly lower among patients who received antiserum than in those who received no treatment [<a href="#rid17">17</a>]. In subsequent systematic reviews of randomized trials in animals, antitoxin therapy using the monoclonal antibodies or human <a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">anthrax immunoglobulin</a> improved survival compared with placebo [<a href="#rid30">30,31</a>], consistent with the benefit of anthrax antiserum in the pre-antibiotic era [<a href="#rid32">32</a>]. However, there was no clear benefit of these agents compared with antibiotics or when added to antibiotics [<a href="#rid30">30</a>]. Evidence in humans is limited to case series; among the 25 patients reported to receive antitoxin or antiserum since 1960, the mortality rate was approximately 35 percent, even among those considered to have fulminant disease [<a href="#rid30">30</a>]. Antitoxin may thus have the greatest value in mass casualty situations where antibiotics are in short supply. Nevertheless, given the severity of systemic anthrax and the paucity of human data, antitoxin administration as early as possible and in conjunction with antibiotic therapy remains a reasonable approach.</p><p class="headingAnchor" id="H108206564"><span class="h3">Raxibacumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">Raxibacumab</a>, a human IgG1-gamma monoclonal antibody directed against protective antigen, was found to be effective for the treatment of anthrax in randomized trials involving rabbits, monkeys, and dogs [<a href="#rid33">33,34</a>]. In 2012, raxibacumab was approved by the US Food and Drug Administration for the treatment of inhalation anthrax [<a href="#rid35">35</a>].</p><p><a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">Raxibacumab</a> is given as a single dose following premedication with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>; dosing recommendations are as follows [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Adults and children &gt;50 kg: 40 mg/kg IV</p><p class="bulletIndent1"><span class="glyph">●</span>Children 15 kg to 50 kg: 60 mg/kg IV</p><p class="bulletIndent1"><span class="glyph">●</span>Children 15 kg or less: 80 mg/kg</p><p></p><p>The efficacy of <a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a> has been systematically evaluated only in animals (see <a class="local">'Antitoxins'</a> above); it is not possible to perform efficacy trials in humans given that inhalation anthrax is both rare and lethal. However, in phase II safety studies in humans, the therapeutic levels of the antibody achieved in humans were equal to or greater than those that provide protection in animal models [<a href="#rid37">37</a>]. Common adverse effects in 326 healthy humans included rash, extremity pain, pruritus, and drowsiness [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1756083600"><span class="h3">Obiltoxaximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">Obiltoxaximab</a>, a monoclonal antibody directed against the protective antigen of <em>B. anthracis</em>, was approved in 2016 by the US Food and Drug Administration for the treatment of inhalation anthrax (in combination with antimicrobial therapy) [<a href="#rid38">38,39</a>]. The evidence supporting its efficacy comes from studies in animal models of inhalational anthrax. </p><p><a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">Obiltoxaximab</a> is given as a single dose following premedication with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>; dosing recommendations are as follows [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight &gt;40 kg: 16 mg/kg IV</p><p class="bulletIndent1"><span class="glyph">●</span>Weight 15 to 40 kg: 24 mg/kg IV</p><p class="bulletIndent1"><span class="glyph">●</span>Weight ≤15 kg: 32 mg/kg IV</p><p></p><p>The efficacy of <a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">obiltoxaximab</a> has been systematically evaluated only in animals (see <a class="local">'Antitoxins'</a> above); it is not possible to perform efficacy trials in humans given that inhalation anthrax is both rare and lethal. The most common adverse effects in trials of 320 humans included headache, pruritus, upper respiratory tract infection, cough, vessel puncture site bruise, infusion site swelling, urticaria, nasal congestion, infusion site pain, and pain in an extremity [<a href="#rid39">39</a>]. Obiltoxaximab was discontinued in 8 of 320 individuals (2.5 percent) due to hypersensitivity reactions or anaphylaxis.</p><p class="headingAnchor" id="H108206570"><span class="h3">Anthrax immunoglobulin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">Anthrax immunoglobulin</a> is derived from the plasma of <a class="drug drug_general" data-topicid="8625" href="/d/drug information/8625.html" rel="external">Anthrax Vaccine Adsorbed</a> (AVA)-immunized persons and is used in combination with antimicrobial therapy [<a href="#rid40">40,41</a>]. Anthrax immunoglobulin neutralizes toxins produced by <em>B. anthracis</em>.</p><p>Nineteen patients with anthrax were treated with <a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">anthrax immunoglobulin</a> and antimicrobial therapy under an expanded access program [<a href="#rid41">41</a>]. Three had inhalation anthrax, one had gastrointestinal anthrax, and 15 had injection anthrax caused by contaminated heroin. Of these patients, 13 survived, including two of the three patients with inhalation anthrax.</p><p>The safety of <a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">anthrax immunoglobulin</a> was tested in 72 healthy human volunteers [<a href="#rid41">41</a>]. The most common side effects were headache, back pain, nausea, and infusion site pain and swelling.</p><p class="headingAnchor" id="H64397993"><span class="h2">Adjunctive therapies</span></p><p class="headingAnchor" id="H1128366051"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids should be considered as adjunctive therapy for patients with anthrax meningitis, cutaneous anthrax with extensive edema involving the head and neck, anthrax in the setting of recent glucocorticoid therapy, or anthrax with vasopressor-resistant shock [<a href="#rid1">1</a>]. Supporting data are limited and there may be no benefit for reducing the inflammation resulting from toxin-mediated tissue edema. Small observational studies of patients with cutaneous anthrax of the head and neck suggest possible benefit [<a href="#rid42">42,43</a>]. A retrospective review of 70 cases of anthrax meningoencephalitis from 1966 to 2002 reported an overall mortality rate of 94 percent, but, among 10 patients treated with glucocorticoids as an adjunct to antimicrobial therapy, mortality was 80 percent [<a href="#rid19">19</a>]. However, it is not possible to draw conclusions from such a small study.</p><p class="headingAnchor" id="H1135541136"><span class="h3">Pleural fluid drainage</span><span class="headingEndMark"> — </span>Pleural fluid drainage has been associated with improved survival in a case series of 82 patients with inhalation anthrax [<a href="#rid17">17</a>]. Drainage of both pleural fluid and ascites is thought to improve survival by reducing the toxin level and by decreasing mechanical lung compression [<a href="#rid1">1,15</a>]. Pleural fluid should be drained early and aggressively; chest tubes are preferred over thoracentesis because many effusions require prolonged drainage. Thoracotomy or video-assisted thoracic surgery might be required to remove gelatinous or loculated pleural effusions.</p><p class="headingAnchor" id="H1132981115"><span class="h3">Managing complications of meningitis</span><span class="headingEndMark"> — </span>Individuals with anthrax meningitis should be managed in a neuro-critical care unit or in consultation with a neuro-critical care specialist, if possible. Intracranial and subarachnoid hemorrhage are frequent complications [<a href="#rid44">44</a>]. Other potential complications include systemic hypertension or hypotension, elevated intracranial pressure, and cerebrovascular vasospasm. </p><p class="headingAnchor" id="H1568457007"><span class="h3">Other invasive procedures</span><span class="headingEndMark"> — </span>Ascites should be drained; drainage of ascites is done preferably with continuous drainage, although in resource-limited situations repeated drainage is acceptable [<a href="#rid15">15</a>]. Hemodynamically significant pericardial effusions should also be drained. Surgery should not be performed for cutaneous anthrax since it can lead to dissemination and poor outcomes. Tracheostomy may be required for patients with airway obstruction and surgery may be required for large or circumferential extremity lesions causing compartment syndrome. Surgery may be indicated for patients with gastrointestinal anthrax to address potentially fatal complications, including bowel ischemia, necrosis, and perforation. For injection anthrax, surgery may be performed to obtain diagnostic specimens and to differentiate the infection from necrotizing fasciitis and to remove the necrotic nidus of infection, which may serve as a reservoir for toxin and spores.</p><p class="headingAnchor" id="H1128366218"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Standard sepsis care should be administered to patients with systemic anthrax, including intravenous fluids, vasopressors, blood products, and invasive hemodynamic monitoring as needed.</p><p>Microangiopathic hemolytic anemia, coagulopathy, thrombocytopenia, and hemorrhage occur frequently with anthrax infection; these complications should be managed aggressively and may be contraindications to central venous catheter placement [<a href="#rid1">1</a>]. Patients with anthrax may require mechanical ventilation for respiratory distress, airway protection (for those with altered mental status), and/or airway edema. Substantial airway edema can occur with cutaneous lesions involving the head, neck, or thorax, and with oropharyngeal lesions. More detailed recommendations for supportive care can be found in the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwwwnc.cdc.gov%2Feid%2Farticle%2F20%2F2%2F13-0687_article&amp;token=l4XEPiERdo6YCULKBVgx%2Bp%2FqCaRAoOA2L%2BXbG1ARz3ADOYwsl64P3xDKIXOyu1Vq%2B42svhzbdNZfp%2B8ajPDasA%3D%3D&amp;TOPIC_ID=15309" target="_blank">CDC guidelines</a>.</p><p class="headingAnchor" id="H2591873941"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Close monitoring is essential for care of patients with systemic anthrax  (<a class="graphic graphic_table graphicRef119773" href="/d/graphic/119773.html" rel="external">table 4</a>). Because there can be a prodromal phase followed by a fulminant phase characterized by sudden decompensation, hospitalized patients should have careful hemodynamic monitoring, including continuous pulse oximetry and telemetry [<a href="#rid1">1</a>]. </p><p>Routine laboratory monitoring includes complete blood count, electrolytes, kidney function tests, liver enzymes and bilirubin, and prothrombin time (PT) and activated partial thromboplastin time (aPTT). Chest radiographs are performed daily until abnormalities (eg, pleural effusion) are stable or improving. Computed tomography (CT) of the chest may be warranted for major changes in clinical status. Echocardiography is performed to evaluate for pericardial effusions, which were reported in 3 of 10 patients with bioterrorism-related inhalational anthrax [<a href="#rid45">45</a>].</p><p>Patients who develop headache, confusion, or other neurologic symptoms should undergo head imaging and repeat lumbar puncture to evaluate for meningitis or other central nervous system complications. </p><p class="headingAnchor" id="H1203606"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Anthrax pre-event vaccination and postexposure vaccination, antimicrobial prophylaxis, and <a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a> prophylaxis are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax"</a>.)</p><p class="headingAnchor" id="H185609414"><span class="h1">PUBLIC HEALTH REPORTING</span><span class="headingEndMark"> — </span>Anthrax is a reportable disease and immediate notification should be made to the local or state health department even if there is only clinical or laboratory suspicion of anthrax or exposure to <em>B. anthracis</em>.</p><p>Healthcare providers should consult their local or state public health departments for specific recommendations for the prevention or treatment of bioterrorism-related anthrax. This is critically important in order to ensure that an antimicrobial regimen is selected to which the isolate is fully susceptible because antibiotic-resistant strains might be intentionally used in such cases.</p><p class="headingAnchor" id="H630243635"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Outcomes of anthrax vary depending on the site(s) of involvement:</p><p class="bulletIndent1"><span class="glyph">●</span>The case-fatality rate of cutaneous anthrax is &lt;2 percent with antibiotic therapy; without therapy, mortality has ranged from 16 to 39 percent [<a href="#rid1">1</a>]. In the preantibiotic era in the early 20<sup>th</sup> century, the mortality rate in patients who received serum (antitoxin) ranged from 0 to 28 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with inhalation anthrax frequently present late in the course of their illness. Prior to 2001, mortality rates for patients with inhalation anthrax were nearly 90 percent [<a href="#rid1">1</a>]. From 2001 to 2012, 8 of 15 patients (53 percent) with inhalation anthrax survived. Patients who survived were diagnosed early, given combination antimicrobial therapy to eradicate <em>B. anthracis</em> and inhibit toxin production, and had aggressive management of pleural effusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Even with antimicrobial therapy and modern intensive care, the mortality rates of injection, gastrointestinal, and inhalation anthrax have been estimated to be 28 percent, ≥40 percent, and 45 percent, respectively [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With treatment, the mortality rate for anthrax meningitis approaches 100 percent [<a href="#rid1">1,2</a>].</p><p></p><p class="headingAnchor" id="H3580462221"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109936.html" rel="external">"Society guideline links: Anthrax"</a>.)</p><p class="headingAnchor" id="H193170897"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contact public health officials</strong> – In the United States, anthrax is an immediately notifiable disease, and clinicians should contact the state health department for assistance in diagnosis and treatment as soon as there is reasonable suspicion for anthrax. (See <a class="local">'Public health reporting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> <strong>of systemic anthrax treatment</strong> – Systemic anthrax includes gastrointestinal, injection, or inhalation anthrax; anthrax meningitis; cutaneous anthrax with systemic involvement; or bacteremia. All patients with systemic anthrax should be hospitalized, be evaluated for meningitis, and urgently receive combination intravenous (IV) antimicrobial therapy and antitoxin therapy. The latter includes the monoclonal antibodies <a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a> and <a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">obiltoxaximab</a> as well as <a class="drug drug_general" data-topicid="100615" href="/d/drug information/100615.html" rel="external">anthrax immunoglobulin</a>; in the United States, these antibody-based therapies are only available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fanthrax%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLErX9qS7Bbsq3%2BGddqmcxuNIBIvPCZHzH4n0BabIMWtt&amp;TOPIC_ID=15309" target="_blank">Centers for Disease Control and Prevention (CDC)</a>, usually by way of the state health department. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment regimens for systemic anthrax</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Meningitis </strong>– For patients with systemic anthrax in whom meningitis is suspected or cannot be ruled out, we suggest IV therapy with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> <strong>plus</strong> <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> <strong>plus</strong> <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>  (<a class="graphic graphic_table graphicRef96170" href="/d/graphic/96170.html" rel="external">table 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also recommend antitoxin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Meningitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic anthrax without meningitis</strong> – For patients with systemic anthrax (eg, inhalation anthrax) without meningitis, we suggest IV therapy with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> <strong>plus</strong> either <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> or <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>  (<a class="graphic graphic_table graphicRef74184" href="/d/graphic/74184.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also recommend antitoxin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Systemic anthrax without meningitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of antimicrobial therapy </strong>– The initial antimicrobial regimen is continued until the patient is clinically stable and for at least three weeks (for meningitis) or two weeks (for systemic anthrax without meningitis). If aerosol exposure has occurred, the patient should then switch to single oral agent  (<a class="graphic graphic_table graphicRef58905" href="/d/graphic/58905.html" rel="external">table 1</a>) to complete a postexposure prophylactic course to prevent relapse from surviving <em>B. anthracis</em> spores. (See <a class="local">'Antimicrobial selection and duration'</a> above and  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax", section on 'Antimicrobials'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous anthrax without systemic involvement</strong> – Patients with cutaneous anthrax involving the head or neck and patients with cutaneous anthrax associated with extensive edema should be treated as patients with systemic involvement. Otherwise, patients with cutaneous anthrax without systemic involvement can receive a single oral antimicrobial agent. For nonpregnant adults, we suggest <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For pregnant, lactating, and postpartum women, we suggest ciprofloxacin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For children, we suggest ciprofloxacin <strong>or</strong>, for amoxicillin-susceptible strains, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For bioterrorism-associated cases and other cases in which an aerosol exposure is suspected, the duration of therapy is 60 days. For naturally acquired infection (eg, animals with anthrax, hides from animals with anthrax), the duration of therapy is 7 to 10 days. (See <a class="local">'Cutaneous anthrax without systemic involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapies</strong> – Adjunctive therapies include glucocorticoids (for systemic anthrax, meningitis, or cutaneous anthrax with extensive edema involving the head and neck), early and aggressive pleural fluid drainage with chest tubes, and management of complications of meningitis (such as intracerebral hemorrhage or elevated intracranial pressure). (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care and monitoring</strong> – Standard sepsis care should be administered to patients with systemic anthrax, including IV fluids, vasopressors, blood products, and invasive hemodynamic monitoring as needed. (See <a class="local">'Supportive care'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hendricks KA, Wright ME, Shadomy SV, et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014; 20.</a></li><li><a class="nounderline abstract_t">Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014; 133:e1411.</a></li><li><a class="nounderline abstract_t">Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis 2014; 20.</a></li><li><a class="nounderline abstract_t">Pillai SK, Huang E, Guarnizo JT, et al. Antimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature Review. Health Secur 2015; 13:355.</a></li><li><a class="nounderline abstract_t">Lightfoot N, Scott R, Turnbull B. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 1990; 68:95.</a></li><li><a class="nounderline abstract_t">Doğanay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991; 23:333.</a></li><li><a class="nounderline abstract_t">Turnbull PC, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004; 42:3626.</a></li><li><a class="nounderline abstract_t">Maxson T, Kongphet-Tran T, Mongkolrattanothai T, et al. Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019. Clin Infect Dis 2022; 75:S373.</a></li><li><a class="nounderline abstract_t">Luna VA, King DS, Gulledge J, et al. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007; 60:555.</a></li><li><a class="nounderline abstract_t">Bakici MZ, Elaldi N, Bakir M, et al. Antimicrobial susceptibility of Bacillus anthracis in an endemic area. Scand J Infect Dis 2002; 34:564.</a></li><li><a class="nounderline abstract_t">Ross CL, Thomason KS, Koehler TM. An extracytoplasmic function sigma factor controls beta-lactamase gene expression in Bacillus anthracis and other Bacillus cereus group species. J Bacteriol 2009; 191:6683.</a></li><li><a class="nounderline abstract_t">Beharry Z, Chen H, Gadhachanda VR, et al. Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis. Biochem Biophys Res Commun 2004; 313:541.</a></li><li class="breakAll">CLSI. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or
Fastidious Bacteria. 3rd ed. CLSI guideline M45. Wayne, PA: Clinical and Laboratory Standards Institute;
2016.</li><li class="breakAll">Anthrax. In: Red Book: 2021–2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2021. p.196.</li><li><a class="nounderline abstract_t">Bower WA, Hendricks K, Pillai S, et al. Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident. MMWR Recomm Rep 2015; 64:1.</a></li><li><a class="nounderline abstract_t">Katharios-Lanwermeyer S, Holty JE, Person M, et al. Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880. Clin Infect Dis 2016; 62:1537.</a></li><li><a class="nounderline abstract_t">Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270.</a></li><li><a class="nounderline abstract_t">Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis 2005; 5:287.</a></li><li><a class="nounderline abstract_t">Lanska DJ. Anthrax meningoencephalitis. Neurology 2002; 59:327.</a></li><li><a class="nounderline abstract_t">Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002; 46:936.</a></li><li><a class="nounderline abstract_t">Meaney-Delman D, Rasmussen SA, Beigi RH, et al. Prophylaxis and treatment of anthrax in pregnant women. Obstet Gynecol 2013; 122:885.</a></li><li><a class="nounderline abstract_t">Giamarellou H, Kolokythas E, Petrikkos G, et al. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 1989; 87:49S.</a></li><li class="breakAll">Food and Drug Administration. Prescription Drug Products: Doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). In: Federal Register, November 2, 2001.</li><li class="breakAll">Food and Drug Administration. Cipro (ciprofloxacin hydrochloride) for inhalation anthrax. http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130709.htm (Accessed on July 09, 2014).</li><li><a class="nounderline abstract_t">Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 2008; 14.</a></li><li><a class="nounderline abstract_t">Huang E, Pillai SK, Bower WA, et al. Antitoxin Treatment of Inhalation Anthrax: A Systematic Review. Health Secur 2015; 13:365.</a></li><li><a class="nounderline abstract_t">Lucchesi PF. Serum treatment of 19 cases of anthrax including one of external, internal and bacteremic type. Am J Med Sci 1932; 183:795.</a></li><li><a class="nounderline abstract_t">Lucchesi PF, Gildersleeve N. The treatment of anthrax. JAMA 1941; 116:1506.</a></li><li><a class="nounderline abstract_t">Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med 1986; 151:71.</a></li><li><a class="nounderline abstract_t">Hesse EM, Godfred-Cato S, Bower WA. Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review. Clin Infect Dis 2022; 75:S432.</a></li><li><a class="nounderline abstract_t">Slay RM, Cook R, Hendricks K, et al. Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins. Clin Infect Dis 2022; 75:S441.</a></li><li><a class="nounderline abstract_t">Hendricks K, Person MK, Bradley JS, et al. Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880-2018: A Systematic Review. Clin Infect Dis 2022; 75:S341.</a></li><li><a class="nounderline abstract_t">Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135.</a></li><li><a class="nounderline abstract_t">Barochia AV, Cui X, Sun J, et al. Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis 2012; 205:818.</a></li><li class="breakAll">US Food and Drug Administration. FDA News Release. FDA approves raxibacumab to treat inhalational anthrax. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 02, 2013).</li><li class="breakAll">Raxibacumab prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf (Accessed on January 03, 2013).</li><li><a class="nounderline abstract_t">Nabel GJ. Protecting against future shock--inhalational anthrax. N Engl J Med 2009; 361:191.</a></li><li class="breakAll">US Food and Drug Adminisration. FDA News Release. FDA approves new treatment for inhalation anthrax. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491470.htm (Accessed on April 04, 2016).</li><li class="breakAll">ANTHIM (obiltoxaximab) injection, for intravenous use - Highlights of prescribing information. http://www.anthim.com/download/pdf/ANTHIM-prescribing-information.pdf (Accessed on April 04, 2016).</li><li class="breakAll">FDA news release. FDA approves treatment for inhalation anthrax. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm (Accessed on March 27, 2015).</li><li class="breakAll">ANTHRASIL [Anthrax Immune Globulin Intravenous (Human)]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM439812.pdf (Accessed on April 06, 2015).</li><li><a class="nounderline abstract_t">Demirdag K, Ozden M, Saral Y, et al. Cutaneous anthrax in adults: a review of 25 cases in the eastern Anatolian region of Turkey. Infection 2003; 31:327.</a></li><li><a class="nounderline abstract_t">Tahernia AC. Treatment of anthrax in children. Arch Dis Child 1967; 42:181.</a></li><li><a class="nounderline abstract_t">Caffes N, Hendricks K, Bradley JS, et al. Anthrax Meningoencephalitis and Intracranial Hemorrhage. Clin Infect Dis 2022; 75:S451.</a></li><li><a class="nounderline abstract_t">Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933.</a></li></ol></div><div id="topicVersionRevision">Topic 15309 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24447897" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777226" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric anthrax clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457117" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26623698" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antimicrobial susceptibility of Bacillus anthracis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1909051" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antimicrobial susceptibility of Bacillus anthracis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297508" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251548" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17586563" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12238569" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Antimicrobial susceptibility of Bacillus anthracis in an endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717606" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : An extracytoplasmic function sigma factor controls beta-lactamase gene expression in Bacillus anthracis and other Bacillus cereus group species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14697223" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14697223" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14697223" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26632963" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025833" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490913" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Systematic review: a century of inhalational anthrax cases from 1900 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15854884" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of anthrax meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177364" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anthrax meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850294" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084549" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prophylaxis and treatment of anthrax in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589384" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pharmacokinetics of three newer quinolones in pregnant and lactating women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589384" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pharmacokinetics of three newer quinolones in pregnant and lactating women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589384" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pharmacokinetics of three newer quinolones in pregnant and lactating women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18394267" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Conference report on public health and clinical guidelines for anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26690378" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Serum treatment of 19 cases of anthrax including one of external, internal and bacteremic type</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The treatment of anthrax</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3083296" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of anthrax in man: history and current concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251559" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251555" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251560" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880-2018: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587338" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Raxibacumab for the treatment of inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223857" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223857" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223857" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587345" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Protecting against future shock--inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587345" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Protecting against future shock--inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587345" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Protecting against future shock--inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587345" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Protecting against future shock--inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587345" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Protecting against future shock--inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14556058" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cutaneous anthrax in adults: a review of 25 cases in the eastern Anatolian region of Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6067248" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of anthrax in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251558" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Anthrax Meningoencephalitis and Intracranial Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747719" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
